U.S. Other Utilities Stock News

NasdaqCM:SMPL
NasdaqCM:SMPLFood

Does Atkins’ Slowdown and Margin Pressure Reshape the Bull Case For Simply Good Foods (SMPL)?

In recent weeks, Simply Good Foods has faced mounting concerns as Atkins brand sales declined in consecutive quarters and rising costs pressured margins, prompting scrutiny of its growth outlook. Beyond the immediate slowdown, the key question now is whether stronger brands like Quest and OWYN can offset Atkins’ weakness and reshape the company’s long-term earnings mix. We’ll now examine how Atkins’ sales slump and margin pressure affect Simply Good Foods’ existing investment narrative built...
NYSE:BABA
NYSE:BABAMultiline Retail

Is Alibaba Group Holding (BABA) Pricing Reflect Its Recent Share Price Weakness?

If you are wondering whether Alibaba Group Holding's share price offers value right now, or if the market is pricing it fairly, this breakdown will help you connect the current price with what the business may be worth. The stock last closed at US$123.73, with returns of a 4.7% decline over 7 days, a 13.2% decline over 30 days, a 20.6% decline year to date and a 3.1% decline over the past year, set against a 32.1% gain over 3 years and a 42.2% decline over 5 years. Recent headlines around...
NYSE:JBL
NYSE:JBLElectronic

How Jabil’s Higher 2026 Revenue Outlook and GLP‑1 Exposure At Jabil (JBL) Has Changed Its Investment Story

In March 2026, Jabil Inc. reported second-quarter results showing year-on-year growth in sales and net income, and issued third-quarter guidance calling for net revenue between US$8.10 billion and US$8.90 billion, U.S. GAAP operating income of US$398 million to US$458 million, and diluted EPS of US$2.36 to US$2.76. The company also lifted its full-year fiscal 2026 outlook to US$34.00 billion in revenue, underscoring how healthcare exposure and injector-pen manufacturing for weight-loss drugs...
NYSE:ABT
NYSE:ABTMedical Equipment

Assessing Abbott Laboratories (ABT) Valuation After New Flatiron Health Oncology Integration

Abbott Laboratories (ABT) just expanded its cancer diagnostics reach through a new integration with Flatiron Health’s OncoEMR, giving more than 1,600 community cancer centers streamlined access to its Precision Oncology testing portfolio. See our latest analysis for Abbott Laboratories. Despite the oncology integration and other recent moves such as the ESOP related shelf registration and investment in Whoop, Abbott’s 30 day share price return of 10.29% and year to date share price return of...
NYSE:PL
NYSE:PLProfessional Services

A Look At Planet Labs (PL) Valuation After Shelf Registration And Wider Losses In Latest Earnings

Planet Labs PBC (PL) is back in focus after filing a US$680.7m shelf registration tied to an ESOP related offering, alongside fresh quarterly results, wider net losses, and new revenue guidance. See our latest analysis for Planet Labs PBC. After the shelf filing and earnings release, Planet Labs PBC’s 1-day share price return of 9.87% contrasts with a 7-day share price return of negative 13.18%. A 90-day share price return of 55.73% sits alongside a 1-year total shareholder return of about...
NYSEAM:KULR
NYSEAM:KULRElectrical

KULR Technology Group (KULR) Q4 Loss Of US$44.3 Million Tests Bullish Growth Narratives

KULR Technology Group (KULR) closed FY 2025 with fourth quarter revenue of US$2.9 million and a basic EPS loss of US$0.97, alongside a trailing twelve month EPS loss of US$1.56 on revenue of US$16.2 million. Over the last few quarters, the company has reported revenue between US$2.4 million and US$6.9 million per quarter, while quarterly EPS has ranged from a loss of US$0.54 to a gain of US$0.22. This leaves investors focusing on how quickly these top line changes might translate into...
NasdaqCM:FTLF
NasdaqCM:FTLFPersonal Products

FitLife Brands (FTLF) Margin Compression In FY 2025 Tests Bullish Growth Narratives

FitLife Brands (FTLF) has just closed out FY 2025 with fourth quarter revenue of US$25.9 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$81.5 million and EPS of US$0.68 that investors will be watching against the prior year’s figures. Over recent quarters the company has seen revenue move from US$15.0 million in Q4 FY 2024 to US$25.9 million in Q4 FY 2025, while quarterly EPS shifted from US$0.23 to US$0.17, setting the backdrop for the latest full year read on...
NasdaqGS:CHKP
NasdaqGS:CHKPSoftware

Check Point Software Technologies (CHKP) Margin Expansion To 38.8% Tests Bearish EPS Decline Narrative

Check Point Software Technologies (CHKP) closed out FY 2025 with fourth quarter revenue of US$744.9 million and basic EPS of US$2.85, while full year trailing EPS reached US$9.85 on revenue of US$2.7 billion and earnings grew 25% over the past 12 months. Over the last few reported periods, revenue has moved from US$703.7 million in Q4 2024 to US$744.9 million in Q4 2025, with quarterly basic EPS ranging from US$1.77 in Q1 2025 to US$3.34 in Q3 2025 and trailing net income rising from US$845.7...
NasdaqGS:DWSN
NasdaqGS:DWSNEnergy Services

Dawson Geophysical (DWSN) Returns To Quarterly Profit Challenging Volatility‑Focused Narratives

Dawson Geophysical (DWSN) closed out FY 2025 with fourth quarter revenue of US$26.9 million and basic EPS of US$0.02, alongside net income of US$0.6 million. This set a cleaner finish to a year where the trailing twelve month figures still show a loss of US$1.9 million on US$75.6 million of revenue and a basic EPS loss of US$0.06. Over recent quarters the company has seen quarterly revenue range from US$9.9 million to US$26.9 million, with EPS moving between a loss of US$0.08 and a profit of...
NasdaqGS:IDYA
NasdaqGS:IDYABiotechs

A Look At IDEAYA Biosciences (IDYA) Valuation After Early IDE849 And IDE161 Combination Trial Activity

IDEAYA Biosciences (IDYA) recently reported the first patient enrolled in a Phase 1 trial combining IDE849, a DLL3 targeting antibody drug conjugate, with PARG inhibitor IDE161 in several DLL3 upregulated solid tumors. See our latest analysis for IDEAYA Biosciences. The Phase 1 combination update has come as IDEAYA’s share price has eased slightly in the short term, with a 7 day share price return of 3.47% and a 1 year total shareholder return close to 100%. This reflects how recent trial...
NYSE:ABM
NYSE:ABMCommercial Services

ABM Industries (ABM) Valuation Check After Recent Share Price Weakness

ABM Industries stock: recent returns and business mix in focus ABM Industries (ABM) has drawn investor attention after a one-month return of about a 13% decline, adding to a past three-month drop of roughly 9%. This performance has invited closer inspection of its fundamentals. See our latest analysis for ABM Industries. With the share price at $38.70, ABM Industries has seen weaker momentum recently, with a 30 day share price return of a 13.44% decline and a 1 year total shareholder return...
NYSE:KOS
NYSE:KOSOil and Gas

Is It Time To Reassess Kosmos Energy (KOS) After Its Strong Year To Date Rally?

If you are wondering whether Kosmos Energy's share price still reflects its underlying worth, the recent moves in the stock make that question especially timely. The stock last closed at US$2.78, with returns of 2.2% over 7 days, 19.3% over 30 days, 211.4% year to date and 23.6% over 1 year, set against a 64.3% decline over 3 years and a 9.2% decline over 5 years. Recent news coverage has focused on Kosmos Energy's positioning within the energy sector and how investors are reacting to...
NYSE:ROK
NYSE:ROKElectrical

Will Rockwell Automation's (ROK) ROKStudios Autonomy Push Reframe Its AI Disruption Narrative?

In late March 2026, Rockwell Automation released a new season of its ROKStudios executive video series, spotlighting manufacturing leaders across EMEA discussing cyber resilience, workforce transformation, packaging innovation, and the shift from traditional automation to more autonomous industrial operations. This content push underscores how Rockwell is positioning itself at the center of industry debates on digital complexity, resilience, and AI-enabled industrial workflows, aligning its...
NYSE:UWMC
NYSE:UWMCDiversified Financial

Insider Share Sales Amid Two Harbors Deal Talks Might Change The Case For Investing In UWM Holdings (UWMC)

In late March 2026, UWM Holdings CEO Mat Ishbia and SFS Holding Corp sold 3,001,722 Class A shares, shortly after the company reported fourth-quarter 2025 revenue of US$945.00 million that exceeded forecasts and announced advisory and proxy work around its proposed acquisition of Two Harbors Investment Corp. This combination of insider selling, stronger-than-expected quarterly results, and an active acquisition process highlights a period of meaningful corporate change and heightened...
NasdaqGS:SIMO
NasdaqGS:SIMOSemiconductor

Silicon Motion Targets Auto Grade NAND To Balance AI And PC Cycles

Silicon Motion Technology (NasdaqGS:SIMO) is expanding its automotive grade NAND storage controller portfolio for connected and AI focused vehicles. The company is aligning products with automotive safety and cybersecurity standards such as AEC-Q100, ISO 26262, ISO 21434, and ASPICE Level 3. Its embedded storage solutions are being tailored for advanced driver-assistance systems and autonomous driving platforms. For readers following NasdaqGS:SIMO, this push into automotive storage sits on...
NasdaqGM:FUTU
NasdaqGM:FUTUCapital Markets

How Futu’s Zacks Rank Upgrade and Brighter Earnings Outlook Will Impact Futu Holdings (FUTU) Investors

Futu Holdings Limited recently received an upgrade to a Zacks Rank #1 (Strong Buy), reflecting a shift toward more positive analyst earnings estimates and sentiment around its profit outlook. This change highlights how analyst estimate revisions can influence perceptions of Futu’s earnings power and the sustainability of its international, technology-led brokerage model. We’ll now examine how this Zacks Rank upgrade and brighter earnings outlook interact with Futu’s existing investment...
NYSE:ABBV
NYSE:ABBVBiotechs

Is It Too Late To Consider AbbVie (ABBV) After Its Recent Share Price Swings?

If you are wondering whether AbbVie at around US$214.98 is a fair deal or a stretch at current levels, this article walks through what the numbers are actually saying about the stock's value. The share price performance has been mixed, with a 3.8% gain over the last 7 days, an 8.2% decline over the last 30 days, a 6.2% decline year to date, an 8.3% return over 1 year, and very large gains of 49.0% and 147.4% across 3 and 5 years. Recent attention on AbbVie has focused on its position as a...
NasdaqGS:BTSG
NasdaqGS:BTSGHealthcare

A Look At BrightSpring Health Services (BTSG) Valuation After Recent Share Price Pullback

What BrightSpring’s recent performance data means for investors BrightSpring Health Services (BTSG) has attracted attention after recent trading data showed a 1.4% decline over the past day and a 6.2% pullback over the past week, alongside positive longer term returns. See our latest analysis for BrightSpring Health Services. Despite the recent 1-day and 7-day share price declines, BrightSpring’s 90-day share price return of 12.23% and very large 1-year total shareholder return of 131.19%...
NasdaqGS:SMCI
NasdaqGS:SMCITech

Why Super Micro Computer (SMCI) Is Down 6.4% After DOJ Export-Control Indictment Tied To Nvidia Servers

The U.S. Justice Department has unsealed an indictment against three individuals linked to Super Micro Computer for allegedly diverting advanced Nvidia-powered servers worth about US$2.50 billions to Chinese customers in breach of U.S. export controls, triggering multiple shareholder class actions accusing the company of misleading disclosures on sales and compliance. Although Super Micro itself has not been named as a defendant, the involvement of a co-founder, governance upheaval, and...
NasdaqCM:DNTH
NasdaqCM:DNTHBiotechs

Dianthus Therapeutics (DNTH) Is Up 6.2% After Early CAPTIVATE “GO” Decision And FDA Alignment - Has The Bull Case Changed?

Dianthus Therapeutics recently reported an early “GO” decision in its late-stage CAPTIVATE trial of claseprubart for chronic inflammatory demyelinating polyneuropathy, after meeting interim responder goals ahead of schedule. The US FDA also agreed to multiple company-proposed changes across claseprubart’s development program, including updated screening criteria, lab work, and autoimmune safety monitoring, potentially streamlining current and future studies. We’ll now examine how the early...
NasdaqGS:HSAI
NasdaqGS:HSAIAuto Components

Will Profit Rebound and Sharpa Physical AI Deal Change Hesai Group's (HSAI) Narrative

Hesai Group recently reported its fourth-quarter and full-year 2025 results, turning a prior-year loss into net income of CNY 435.88 million on CNY 3,027.57 million in sales, and entered a 2026 Supply of Products Framework Agreement under which it will provide LiDAR products and robotic actuators plus manufacturing and support services to Sharpa. By pairing improved profitability with a new Physical AI-focused partnership that bundles hardware and integration services, Hesai is broadening...
NasdaqGS:ARQT
NasdaqGS:ARQTBiotechs

Assessing Arcutis Biotherapeutics (ARQT) Valuation After Positive ZORYVE Infant Phase 2 Trial Results

Arcutis Biotherapeutics (ARQT) is back in focus after new INTEGUMENT-INFANT Phase 2 data on ZORYVE cream 0.05% in infants with mild to moderate atopic dermatitis, supporting a planned supplemental New Drug Application. See our latest analysis for Arcutis Biotherapeutics. The new clinical data arrives after a mixed stretch for the shares, with a 1-day share price return of 10.45% and 7-day share price return of 7.92% contrasting with a 30-day share price return decline of 12.64%. However, a...
NasdaqGS:IDXX
NasdaqGS:IDXXMedical Equipment

Idexx Laboratories (IDXX) Valuation Check After New Cancer Dx Panel Launch In The United Kingdom

IDEXX Laboratories (IDXX) has drawn fresh attention after introducing its IDEXX Cancer Dx Panel in the United Kingdom, offering blood test based early detection of lymphoma in at risk dogs and expanding its veterinary diagnostics reach. See our latest analysis for IDEXX Laboratories. Despite the product launch and earlier trading spikes, momentum in the share price has cooled, with a 30 day share price return of a 14.44% decline and a year to date share price return of a 16.13% decline, while...
NYSE:AFL
NYSE:AFLInsurance

Is It Time To Reassess Aflac (AFL) After Recent Cyberattack And Mixed Valuation Signals

If you are wondering whether Aflac at around US$109.64 is offering fair value or a potential bargain, this article walks through what the current price might be indicating. The stock has been relatively steady recently, with a 2.3% return over the last 7 days, a 3.3% decline over 30 days, and returns of 0.5% decline year to date and 0.2% decline over 1 year, set against much stronger 3 year and 5 year returns of 81.6% and 137.7%. Recent coverage around Aflac has focused on its role as a...